{"preliminary_commentary":{"by_channel":{"youtube":3,"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"CHIMERA","nct_id":"NCT06155279","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=chimera-nct06155279. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CHIMERA","arms":[{"description":"Single arm Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab\n\nThe neoadjuvant systemic treatment will be based on three cycles of pembrolizumab 200 mg flat dose in combination with standard doses of cisplatin (75 mg/sm) or carboplatin (AUC 5) and pemetrexed (500 mg/sm) administered intra-venous every 3 weeks.\n\nThe surgical intervention of pleurectomy/decortication will be planned to occur within 6 weeks after the completion of neoadjuvant treatment.\n\nThe adjuvant systemic treatment will be based on 14 cycles of pembrolizumab 200 mg flat dose administered intra-venous every 3 weeks. Patients should be able to start pembrolizumab following surgery as soon as clinically feasible and within 10 weeks from surgery.","label":"Single arm","type":"EXPERIMENTAL"}],"collaborators":["MSD Italia S.r.l."],"completion_date":{"date":"2027-03","type":"ESTIMATED"},"conditions":["Pleural Mesothelioma"],"enrollment":{"count":41,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"}],"last_update":"2026-01-13","lead_sponsor":"Istituto Oncologico Veneto IRCCS","official_title":"Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed as Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-12-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"Primary endpoint - To evaluate the activity of neo-adjuvant treatment by the determination of pathological complete response rate (pCR)","timeFrame":"Pathological complete response will be evaluated following neoadjuvant treatment and within 6 weeks after the last dose of study intervention."}],"references":[],"start_date":{"date":"2024-11-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)","url":"https://clinicaltrials.gov/study/NCT06155279"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/chimera-nct06155279"}